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Abstract
Non-selective beta blockers (NSBB) are commonly used 
to prevent portal hypertensive bleeding in cirrhotics. 
Nevertheless, in the last years, the use of NSBB in 
critically decompensated patients, especially in those 
with refractory ascites, has been questioned, mainly 
for an increased risk of mortality and worsening of 
systemic hemodynamics. Moreover, even if NSBB have 
been reported to correlate with a higher risk of renal 
failure and severe infection in patients with advanced 
liver disease and hypotension, their use has been 
associated with a reduction of risk of spontaneous bac-
terial peritonitis, modification of gut permeability and 
reduction of bacterial translocation. This manuscript 
systematically reviews the published evidences about 
harms and benefits of the use of NSBB in patients with 
decompensated cirrhosis. 
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Core tip: In this review, we’ve critically analyzed the 
recent evidence on the role played by non-selective beta 
blockers in patients with decompensated liver disease.
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INTRODUCTION
Cirrhosis is among the leading causes of death worldwide 
and hepatocellular carcinoma and complications of portal 
hypertension (PH) represent the most frequent causes of 
death.
PH is characterized by a systemic hyperdynamic 
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circulation, with increase of cardiac output (CO) and 
heart rate (HR), and reduction of mean arterial pressure 
(MAP) and systemic vascular resistances[1]. The degree 
of PH correlates with the severity of hyperdynamic circula­
tion, while the absence of hemodynamic imbalance (i.e., 
preserved right heart preload) is associated with better 
prognosis[2]. 
Ascites, esophageal varices, encephalopathy and/
or jaundice are the main features of decompensated 
cirrhosis. Ascites represents the first clinical sign of 
decompensation in 30%­50% of patients, being the 
incidence about 50% within 10 years[3]. Refractory 
ascites occurs in 5% to 10% of cases, leading to a 
significant shortening in survival[4]. Oesophageal varices 
occur in about 50% of cirrhotic patients[5] being the 
incidence of first variceal bleeding estimated to be about 
12%­15% per year, and the mortality of 15%­20% 
for every episode[6]. Varices mainly develop due to 
increased PH, but Fernandez et al[7] reported that their 
formation was also modulated by active angiogenesis, 
and not by a simple mechanism of vasodilation. 
Moreover, several external factors, such surgery, 
bacterial infections or bleeding, represent severe trigger 
factors for derangement of hemodynamic; for instance, 
infection seemed more frequent in those patients who 
developed an acute­on­chronic liver failure (32.6% vs 
21.8%, P < 0.01)[8]. Phillip et al[9] showed that removal 
of > 5 L of ascites determined a significant reduction 
of MAP and SVR, which is usually associated with a 
counterbalancing increase of CO[10]. The hemodynamic 
imbalance after LVP led to an increased risk of renal 
dysfunction, and subsequently to an increased mortality, 
according to the well­defined Paracentesis Induced 
Circulatory Dysfunction (PICD)[11].
Heart dysfunction has been shown in decompensat­
ed cirrhosis[12], being caused both by organic (i.e., 
alcoholic or septic cardiomyopathy) and/or functional [i.e., 
cirrhotic cardiomyopathy (CM)] factors. CM is mainly 
due to chronic increase of pro­inflammatory cytokines, 
impairment of systemic and regional hemodynamic, and 
beta­adrenergic receptor desensitization, with reversible 
impairment of systolic contractility, diastolic function and 
electrophysiological activity[1,13]. The impaired CO may 
also contribute to a decrease in renal perfusion: For 
instance, Krag et al[14] demonstrated that a lower cardiac 
index was associated with an increased development of 
hepatorenal syndrome within 3 mo (43% vs 5%, P = 
0.04). Although it’s difficult to determine the prevalence 
of CM since it’s usually masked at rest, it could be 
an important cause of multi­organ failure and death 
during stressing conditions, as infection or liver trans­
plantation[15]. 
ROLE OF NON-SELECTIVE BETA 
BLOCKERS IN THE TREATMENT OF PH
Non-selective beta blockers and variceal bleeding
Non­selective beta blockers (NSBB) act reducing portal 
flow and PH by decreasing CO (through β1 receptors) 
and determining splanchnic vasoconstriction (through 
β2 receptors)[16]. In 1981 Lebrec et al[17] demonstrated 
for the first time the effectiveness of NSBB for variceal 
bleeding; the re­bleeding rate was 4% in the treated 
group, compared to 50% in the placebo group.
Several randomized studies confirmed that NSBB 
represent the preferred option in primary prophylaxis 
against no intervention[18] and in preventing re­bleeding 
in combination with endoscopic band ligation[19]. Fur­
thermore, a Cochrane metanalysis[20] confirmed that 
NSBB were as effective as endoscopic band ligation for 
reducing bleeding related mortality [29/567 (5.1%) vs 
37/585 (6.3%); RR = 0.85; 95%CI: 0.53 to 1.39].
However, identification of hemodynamic response 
to NSBB still remains challenging for the hepatologists. 
Heebøll et al[21] demonstrated that only 51/124 (40%) 
of patients with cirrhosis who underwent measurement 
of gradient between portal and hepatic veins (HVPG) 
presented a significant hemodynamic improvement 
(reduction greater than 20% or > 12 mmHg) after NSBB 
use. Moreover, authors did not demonstrate a significant 
association between improvement of HVPG and change 
of HR (P = 0.8), which is commonly used parameter to 
tailor propranolol therapy. 
Importantly, all the trials often ruled out cirrhotics 
with decompensated liver disease (i.e., those with refrac­
tory ascites) from the analysis.
NSBBS IN DECOMPENSATED 
CIRRHOTICS
Serstè et al[22] showed for the first time in 2010 that 
the median survival was extremely reduced in 151 
patients with cirrhosis and refractory ascites treated with 
propranolol (20.0 mo vs 5.0 mo; P = 0.00001); other 
factors associated with higher mortality were Child­Pugh 
class C, hyponatremia and renal failure. These data 
raised several concerns amongst hepatologists[23­25] about 
the use of NSBB in cirrhotics with more advanced liver 
disease. 
First, the group receiving NSBB comprises obviously 
sicker patients, because of higher prevalence of oeso­
phageal varices (77/77 vs 3/74; P = 0.001) and higher 
serum bilirubin (56 mg/dL vs 48 mg/dL, P = 0.01). Second, 
the propranolol dose of 160 mg/d was significantly higher 
(in about half of the patients) than the mean dose used 
in the previous RCTs. Third, mortality was extremely 
higher in the NSBB group (63/77, 85.1%, median sur­
vival time was 5 mo), and there was an increased pre­
valence of sepsis related mortality, which remain difficult 
to explain[25]. 
The French group hypothesized that NSBB use can 
worse hemodynamic after LVP; thus, reduced survival 
could be due to an increased incidence of PICD. A cross­
over study published in 2011[26] including 10 patients 
with refractory ascites, investigated the incidence of PICD 
after LVP when patients were taking NSBB and after 
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drug discontinuation. The authors showed that PICD was 
extremely decreased after propranolol discontinuation 
(1/10 vs 8/10; P = 0.01). The hypothesis was that 
propranolol use determined a reduction of CO and 
consequently an increase of counter­regulatory vaso­
constriction systems, as renin angiotensin aldosterone, 
whose permanent hyper­activation could be associated 
with poorer renal function and reduced paracentesis­free 
interval time. 
The link between NSBB and hemodynamic impair­
ment was explained with the reduced MAP, which is 
a known negative prognostic factor for hyperdynamic 
circulation and progression of liver disease[27]. For instance, 
in the French study by Serstè et al[22], the cohort receiv­
ing propranolol did have lower MAP (90 mmHg vs 83 
mmHg). Nevertheless, NSBB have been shown not to 
reduce MAP after acute i.v. administration[28], and the 
detrimental effects which were seen by the authors 
could have been due to the dose related side effect 
made by propranolol. CO is not usually reduced by NSBB 
introduction[29]. 
The following clinical studies failed to find any asso­
ciation between the use of NSBB and increased risk of 
deaths in decompensated cirrhotics (Table 1). Leithead 
et al[30] analyzed a subgroup of 117 patients with re­
fractory ascites listed for LT, receiving a median dose of 
propranolol of 80 mg/d. They demonstrated that NSBB 
were independently associated with reduced waitlist 
death (adjusted HR = 0.35, P = 0.022), without higher 
prevalence of sepsis related mortality. Moreover, an 
equal survival between patients with refractory ascites 
taking NSBB and patients without NSBB (12/38 vs 8/23; 
P = 0.79) was shown in another smaller single center 
retrospective analysis[31].
Bossen et al[32] not only confirmed similar mid­term 
mortality between 258 patients with refractory ascites 
receiving NSBB and a control group of 330 patients 
(30.8% vs 30.5%; adjusted HR = 1.02, 95%CI: 0.74­1.39) 
retrospectively evaluated, but also showed that dis­
continuation of NSBB was associated with an higher 
mortality (adjusted HR = 5.13, 95%CI: 2.28­11.55). 
In addition, new data seemed to confirm the absence 
of correlation between mortality and NSBB. Pereira et 
al[33] included 163 patients with infection, of whom 104 
were on NSBB. Use of NSBB was associated with lower 
frequency of sepsis (21% vs 42%, P = 0.03), being 3­mo 
survival not different between cohorts (59% vs 63%; P 
= ns). Mallawaarachchi et al[34] showed that 75 patients 
treated with NSBB (67 with carvedilol and 8 propranolol) 
presented equal mortality after a median follow­up time 
of 28.0 mo (60.0% vs 66.7%; P = 0.10); in those with 
moderate or severe ascites, survival was similar in both 
groups (P = 0.67), while it was better in NSBB patients 
in mild ascites (P = 0.02).
In a large multicentric cohort, Bhutta et al[35] con­
firmed that survival was significantly greater in patients 
on NSBB at admission with a median survival of 58 d 
compared to 32 d in patients not on NSBB (P = 0.033). 
No difference was found between those who did or did 
not discontinue NSBB (P = 0.91), being only systolic 
arterial pressure and acute renal failure independent 
predictors of death.
Onali et al[36] evaluating 316 patients (126 with refrac­
tory ascites), showed that those on NSBB (n = 128, 
40.5%) had a higher frequency of previous variceal 
bleeding (50% vs 21%, P < 0.001) and spontaneous 
bacterial peritonitis (27% vs 17%, P = 0.025), but were 
at lower risk of death (16% vs 32%; P = 0.002). At 
multivariate analysis use of NSBB was associated with 
reduced mortality (HR = 0.511, 95%CI: 0.3­0.87, P = 
0.014). 
Finally, in a recent study provided on 349 acute­on 
chronic patients with cirrhosis, Mookerjee et al[37] demon­
strated a significantly lower short term mortality in 
patients on NSBB compared to those without NSBB (24% 
vs 34%, P = 0.048). Interestingly, patients on NSBB 
had less severe progression to the stages of acute­on­
chronic liver failure, and those who discontinued NSBB 
had a higher mortality (37% vs 13%), even if it might be 
due to an independently higher presence of circulatory 
dysfunction.
The association between increased mortality and 
NSBB could be explained with the worsening of an 
already impaired hemodynamics, especially in those who 
experience a greater decrease of cardiac function (i.e., of 
CO) and of MAP. However, in the study by Karagiannakis 
et al[15] in which the decrease of CO (and subsequently of 
cardiac index) has been correlated with a lower survival, 
the used cut­off (1.5 L/m per square meter) is not 
diffusely seen in cirrhotics, even when decompensated[38].
Simultaneous presence of several cofactors, as 
infection, could contribute to the change of clinical sce­
nario, being patients at higher risk of hemodynamic 
derangement if NSBB are not withdrawn.  
Mandorfer et al[39] showed that 245 patients with 
refractory ascites but without infection, taking NSBB, 
experienced a significant reduction in hospitalization 
rate (19.4 d vs 23.9 d per person­year); at mul­
tivariate analysis, NSBB treatment correlated with 
higher transplant­free survival (HR = 0.771; 95%CI: 
0.598­0.993; P = 0.04). The Authors demonstrated a 
correlation between mortality and NSBB only in patients 
experiencing a previous episode of spontaneous bacterial 
peritonitis (SBP), with a significant difference in length of 
hospitalization (NSBB: 33.4 d per person­year; 95%CI: 
31.9­34.9 vs no­NSBB: 28.8 d per person­year; 95%CI: 
27.6­29.9), and impaired transplant­free survival (HR = 
1.644; 95%CI: 1.145­2.361). These data may confirm 
that NSBB could negatively influence hemodynamic 
status in patients with infection, but not that NSBB 
represented a trigger for infection.
However, Galbois et al[40] showed that cirrhotics 
admitted to intensive care unit for sepsis or septic shock 
who were receiving NSBB were not at increased risk of 
early or mid­term mortality (15/26 vs 26/42, P = 0.8; 
and 21/26 vs 28/42; P = 0.27, respectively).
In summary, latest studies seem not to confirm 
correlation between NSBB and mortality. Another meta­
Ferrarese A et al . Beta blockers and portal hypertension
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analysis[41], which comprised 23 and 28 RCTs on primary 
and secondary prophylaxis for variceal bleeding, for a 
total of 4481 patients included (39.8% with ascites), 
extensively confirmed the absence of increased mor­
tality for patients on NSBB. In primary prophylaxis, 
215/955 patients died for bleeding­unrelated causes, in 
a proportion not different between those who were or 
were not on treatment with NSBB (OR = 0.91, 95%CI: 
0.73­1.15). Similarly, in secondary prophylaxis RCTs, 
bleeding­unrelated deaths did not differ between groups 
(189/1143 vs 225/1208; OR = 0.90, 95%CI: 0.67­1.23). 
These data were confirmed in the subgroup taking 120 
mg/d or more of propranolol (48/374 vs 57/309, OR 
= 1.01, 95%CI: 0.55­1.84), and in those with severe 
ascites (124/595 vs 151/627, OR = 0.93, CI: 0.61­1.43).
SECOND GENERATION OF BETA 
BLOCKERS: CARVEDILOL
Carvedilol is a NSBB with mild anti­α1­adrenergic activity. 
It has been shown to be more effective than propranolol 
in reducing HVPG due to the α­1 blockage, which reduces 
intra­hepatic resistances. Its role was investigated for the 
first time more than 20 years ago[42], as a potential tool 
for reducing PH in patients with cirrhosis, with promising 
results. Since then, several studies demonstrated its 
effectiveness in terms of HVPG decrease, after acute 
administration and after chronic treatment[43].
In 2002, Bañares et al[44] demonstrated that 26 
patients receiving carvedilol experienced a greater 
reduction of HVPG than 25 patients taking propranolol 
(­19% ± 2% vs ­12% ± 2%; P < 0.001); the decrease 
of HVPG was higher in patients with more severe liver 
disease (Child­Pugh class B and C vs Child­Pugh class A: 
­25% ± 2% vs ­14% ± 3% respectively). 
Previous studies showed that, in patients with cirr­
hosis, acute administration of carvedilol could enhance 
hypotension and effective hypovolemia, reducing renal 
blood flow and consequently glomerular filtration rate. 
In the study by Bañares et al[44], renal function remained 
stable (glomerular filtration rate from 90 mL/min ± 
4 mL/min to 84 mL/min ± 5 mL/min; P = ns) in both 
groups, suggesting a potential chronic hemodynamic 
adjustment in response to arterial hypotension. Further–
more, the authors confirmed that reductions of HR and CO 
were lower with carvedilol than with propranolol. However, 
MAP was significantly reduced only in the carvedilol group 
(91.4 mmHg ± 2.5 mmHg vs 81.2 mmHg ± 2.9 mmHg; 
P < 0.05; propranolol: 88.6 mmHg ± 4.5 mmHg vs 83.8 
mmHg ± 3.1 mmHg; P = ns). Thus, despite promising 
data, the use of carvedilol as first choice drug remains 
controversial[19], especially in those patients with severely 
impairment of hemodynamic (i.e., refractory ascites), 
because further reduction of MAP could be detrimental 
for organ perfusion. In fact in a recent metanalysis[45] on 
5 studies which analyzed the role of carvedilol in a total of 
90 patients, the number of patients achieving a reduction 
in HVPG to ≥ 20% was markedly higher with carvedilol 
(57/94 vs 33/87), but hypotension occurred in one­third 
Ref. Patients Refractory ascites Propranolol dose/day Follow-up Mortality Sepsis
Serstè et al[22]   74 100% 40 mg (9); 80 mg (31); 
120 mg (1); 160 mg (36)
8 mo 63/77 (P < 0.0001 vs 
No NSBB)
NA
Galbois et al[40]   26 14 (53.8%) NA 6 mo      21/26 (80.8%) 100%
Robins et al[60]   36 100% 48.9 10 mo 18/36 (50%) survival 
18 mo
NA
Mandorfer et al[39] 245 100% 40 mg (20-120) 660 persons/year Higher transplant 
free survival (HR = 
0.771, P = 0.044)
No correlation 
between NSBB and 
SBP (HR = 0.728, P 
= 0.211)
Kimer et al[31]   23 100% 80 mg (40-200) Retrospective      15/23 (65.2%) NA
Leithead et al[30] 159 (119 on propranolol) NA 80 mg (10-240) Retrospective 35/159 (22%) NA
Bossen et al[32] 559   46% NA 12 mo  125/559 (22.5%) NA
Mookerjee et al[37] 164 (propranolol 111; 
nadolol 6; carvedilol 16; 
other 31) 
NA 40 (20-80; propranolol) NA 40/164 vs 63/184 
(24.4% vs 34.1%, P = 
0.048)
NA
Similar 6 and 12-mo 
mortality between 
groups (P = 0.64 and 
0.35 respectively)
Pereira et al[33] 104 NA NA NA 67% vs 69% (P = ns) 21% vs 42% (P = ns)
Mallawaarachchi et al[34] 75 (8 propranolol) NA NA 28 mo 60% vs 66% (P = ns) NA
Bhutta et al[35] 308 (nadolol 155; 
propranolol 64; 
carvedilol 72, other 62)
NA NA NA Mean survival: 58 d 
in NSBB group (vs 32 
d of control group; P 
= 0.033)
NA
Onali et al[36] 126 100% NA 4 mo 20 vs 60 (16% vs 32%; 
P = 0.002) 
NA
Table 1  Available literature on the potential correlation between non-selective beta blockers and mortality in patients with cirrhosis
NA: Not available; NSBB: Non-selective beta blockers; SBP: Spontaneous bacterial peritonitis; ns: No significance.
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more patients than with propranolol.
NON-HEMODYNAMIC EFFECTS OF 
NSBBS IN PH
Several pleiotropic effects of NSBB have been recently 
demonstrated beyond their hemodynamic role[46]. 
In 2003 Abraldes et al[47] compared the incidence 
of complications due to PH in 28 patients responders 
to NSBB; after a follow­up of 8 years, they found that 
the risk of developing ascites (P = 0.025), hepatorenal 
syndrome (P = 0.026), and encephalopathy (P = 0.024) 
were significantly lower than in the 45 patients non­
responders. Another study of Hernández­Gea et al[48] 
demonstrated that an effective treatment (i.e., significant 
reduction of HVPG) with NSBB for primary prophylaxis 
was associated with reduced risk of ascites development 
(19% vs 57% at 3 years, P < 0.001). 
Since bacterial translocation has been widely con­
sidered an important trigger factor for worsening of 
PH, also for the lack of response of immune system in 
cirrhosis[49], and since selective bacterial decontamination 
seems to partly reverse the hemodynamic derangement 
in cirrhosis[50], several studies tried to investigate whether 
NSBB could contribute to PH reduction through a modi­
fication of the protean interactions between the gut and 
the liver.
Propranolol seems to play a role in reduction of bac­
terial translocation, probably increasing bowel motility 
through a sympatholytic action[51]. After the confirmation 
that intestinal permeability was significantly impaired 
in cirrhotic than in controls (lactulose/mannitol ratio: 
0.026 vs 0.014, P = 0.001); we demonstrated that NSBB 
introduction determined a significant improvement of 
intestinal permeability, and reduction of hyper­vasculari­
zation at confocal microscopy[52]. Also Reiberger et 
al[53] showed a reduction of intestinal permeability after 
introduction of NSBB, and a contemporary reduction of 
bacterial translocation [LPS­binding protein: ­16% (P = 
0.018); interleukin­6: ­41% (P < 0.0001)]; interestingly, 
the Authors showed equal effectiveness also in those 
whose HVPG did not significantly reduced after NSBB 
introduction. 
Although a retrospective study on 134 patients with 
cirrhosis and ascites[54] did not show a reduction of SBP 
during therapy with NSBB (6/33 vs 33/101; OR = 0.46, 
P = 0.17), a meta­analysis performed on 4 studies 
demonstrated a significant difference (12.1%, P < 0.001) 
in favor of propranolol in preventing SBP[55].
Bacterial translocation is the main trigger factor for 
infection in cirrhosis, and infection is a known trigger for 
variceal bleeding[46]. Merli et al[56] demonstrated that in 
140 patients with cirrhosis who experienced infection, 
those on NSBB showed a trend towards a lower incidence 
of sepsis (40% vs 57%), septic shock (8% vs 15%), 
hepatorenal syndrome (14% vs 17%) and mortality 
(15% vs 40%).
CONCLUSION AND FUTURE 
PERSPECTIVES
To date, NSBB remain the treatment of choice for pri­
mary and secondary prophylaxis for portal hypertensive 
bleeding, even though new drugs, as statins[57], or new 
generation beta blockers, as carvedilol, may increase 
the rate of hemodynamic response. NSBB use has 
been associated with several pleiotropic characteristics, 
i.e., reduction of bacterial translocation, prevention 
of spontaneous bacterial peritonitis ­ different from 
prevention of bleeding, suggesting a pleiotropic role in 
decompensated cirrhosis. Contrasting data on the use of 
NSBB in sickest patients with decompensated cirrhosis 
made their use controversial. A recent survey[58] about 
629 physicians highlighted the high heterogeneity across 
centers. For instance, refractory ascites was considered 
a contraindication to NSBB use for 36% of responders, 
while for the 61% NSBB have to be withdrawn during 
HRS, highlighting a general lack of consensus across all 
the issues of the survey. A window hypothesis for therapy 
with NSBB in the natural history of cirrhosis was made 
by Krag et al[59]; according to this view, NSBB could 
play a detrimental role for cirrhotics at the earlier stage 
(i.e., for pre­primary prophylaxis) and in the “extremely 
decompensated” phase, in those patients with MAP lower 
than 80 mmHg, decreased baseline CO of those with 
concomitant infections[19]. 
Since infected cirrhotics are those at greater risk of 
variceal bleeding and HVPG has been increased also after 
the resolution of infection[38], attention should be paid 
to a potential increase in the risk of portal hypertensive 
bleeding. In addition, the interplay between propranolol 
and sepsis has to be further investigated with future 
larger studies. 
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